| http://www.w3.org/ns/prov#value | - Daiichi Sankyo Co.???s experimental blood thinner edoxaban was as effective and less risky than standard treatment warfarin in a study that may position the Japanese company to compete with drugmakers including Pfizer Inc., Johnson & Johnson and Bristol-Myers Squibb Co.
|
